IL6 and COVID-19: COVID-19 is characterized as a cytokine release syndrome, in which heightened secretion of TNF-α, IL-1β, IL-6 and many other factors can trigger inflammation, local tissue damage as well as systemic multi-organ failure.10 We first evaluated the circulating levels of TNF-α and IL-1β in COVID-19 patients.